Long COVID Is a Label, Not a Diagnosis

The label is the problem

A patient walks in with eighteen months of brain fog, exertional crash, heart palpitations on standing, and a sleep architecture that's never come back. Their chart says Long COVID. Their workup, if there was one, was a CBC, a CMP, a thyroid panel, and a referral to a wellness influencer's online program.

Long COVID is what conventional medicine writes when it doesn't have a schema for what's happening. It's not wrong that something is happening. It's wrong that "something" is one disease.

In a working integrative clinic, the same label hides at least six distinct mechanistic pictures:

1. Fibrinaloid microclot disease — vascular pattern, cognitive decline, exertion crash.
2. Reactivated latent viruses — EBV, HHV-6, CMV, parvo, sometimes endogenous retroviruses.
3. Mold colonization + biotoxin illness — usually a home or workplace exposure the patient hadn't connected.
4. Mast cell activation syndrome (MCAS) triggered by the infection.
5. Autonomic dysregulation — POTS, dysautonomia, parasympathetic collapse.
6. Methylation / detox capacity failure — MTHFR, COMT, GST polymorphisms that handled life fine until the immune challenge stacked.

Most patients we work up have two or three of these running simultaneously. That's why no single intervention "works." That's why conventional medicine, which is built around single-mechanism diagnoses, can't get traction.

<!-- CHART: Six mechanisms hiding under the "Long COVID" label, with characteristic symptoms and workup -->

Microclots and the vascular-dementia pattern at 35

The cleanest finding of the post-COVID era is also the one conventional medicine has been slowest to operationalize.

Multiple research groups have demonstrated fibrinaloid microclots in post-viral patients — small, persistent fibrin aggregates that don't show up on routine clotting panels and don't break down on the usual fibrinolytic timeline. They occlude small vessels, particularly in the brain. The clinical picture is patients in their thirties with cognitive symptoms that look, on careful exam, more like early vascular dementia than the brain fog of being tired.

What conventional medicine offers them: nothing, because there's no FDA-approved protocol for a problem the standard panels don't pick up.

What an integrative workup does: D-dimer + soluble fibrinogen, ideally microclot imaging where available, then a sequenced approach — nattokinase, lumbrokinase, sometimes triple anticoagulation under close supervision, paired with the rest of the workup so we're not just dissolving clots while leaving the driver in place. (Our full vascular protocol breakdown.)

If your "Long COVID" patient is 32 and presenting with what looks like dementia — this is the first thing you rule out. Not the last.

Reactivated viruses and the immunosuppressant problem

The acute-phase treatment of severe COVID often included sustained steroids and, in subsets, biologic immunosuppressants used off-label. That choice made sense in the acute phase. It also did something we now have to deal with: it suppressed the cellular immune system that keeps latent herpesviruses in check.

The result, in a measurable fraction of post-COVID patients: reactivated EBV, HHV-6, CMV, and parvovirus — sometimes single, often stacked. These are the same viruses that drive a meaningful slice of chronic fatigue syndrome, MS-like presentations, and "treatment-resistant" depression in this population.

The conventional workup almost never includes early-antigen panels for these. So they get missed. So the patient gets a Long COVID label.

The Klinghardt-trained read on this is uncomfortable but worth stating: sustained immunosuppression in an immune-mediated illness is a strategy that has to be used carefully, not reflexively. The patients in our clinic who came in worst weren't the ones with the most severe acute infection — they were the ones whose acute treatment included the longest stretches of immunosuppression. That's an observation, not a politics.

Mold, the second exposure

A pattern we see weekly: patient gets COVID, partially recovers, then never fully bounces back. They assume it's the virus. Workup of the home or office finds a mold exposure that was always there but their immune system was handling. The viral hit took enough capacity off the system that the mold load is now symptomatic.

This is why a mycotoxin urine panel + an ERMI (or HERTSMI-2) of the living environment is on our standard post-viral workup. Skipping it sends patients in circles for years.

(Klinghardt's mold protocol breakdown.)

MTHFR, COMT, and the personalized detox story

This is where the genetics conversation actually matters.

MTHFR, COMT, GST, NAT2, SOD — these are the polymorphisms that govern how you methylate, detoxify, and clear neurotoxins. Most of the time, they're not symptomatic. Under a sustained immune challenge with a stacked toxin load, they become the bottleneck that decides who recovers and who doesn't.

A patient with compound heterozygous MTHFR + slow COMT will accumulate methylated catecholamines and methylated estrogens at a rate that drives the brain-fog/anxiety/insomnia triad we see post-COVID, even when the viral piece has technically cleared. They're not still infected. They're stuck in a methylation log-jam from the inflammation the infection set off. Same label, completely different work.

This is what the MTHFR-driven brain-fog case study (Sarah M., 32) walks through in detail. Same patient archetype, no COVID involvement, almost identical presentation. The mechanism is the bottleneck — not the trigger.

<!-- CHART: MTHFR / COMT / GST decision tree for post-viral patients -->

Autonomic collapse and the POTS overlap

A large fraction of "Long COVID" patients meet criteria for POTS or broader dysautonomia. The autonomic nervous system runs detox, immune coordination, gut motility, hormone signalling, and cerebral perfusion. When it collapses into sustained sympathetic dominance — which infection plus chronic inflammation reliably does — every downstream system falters.

This is why the Klinghardt sequencing puts nervous system work in the foundation, not in the optimization layer. Vagal toning, HRV training, neural therapy, sometimes targeted PEMF, occasionally craniosacral work — these aren't optional add-ons. Without a parasympathetic-dominant baseline, no detox protocol clears, no antiviral works fully, no methylation support lands. (POTS root-cause workup.)

What we actually do

In our clinic, a "Long COVID" intake gets:

1. Full microclot workup (D-dimer, soluble fibrinogen, imaging where available).
2. Reactivated-virus panel with early antigens, not just IgG/IgM.
3. Mycotoxin urine + home ERMI.
4. Mast cell labs (tryptase, prostaglandin D2, NMH).
5. Autonomic profile (HRV, orthostatic vitals, tilt-table where indicated).
6. Methylation + detox genetics (MTHFR, COMT, GST, NAT2, SOD2).
7. Thyroid + adrenal + sex hormones (DUTCH, full thyroid panel).
8. GI-MAP for gut-brain axis.
9. Nervous system + Klinghardt 5-level assessment for what floor the patient is actually stuck on. (Framework.)

Then we sequence. Drainage first. Terrain second. Specific drivers third. Detox fourth. Nervous system woven through every phase. Optimization last.

That's the difference between Long COVID the label and post-viral mechanistic recovery the work.

The point

If your clinician handed you the Long COVID label without running most of the workup above, you don't have a diagnosis. You have a holding pen.

That doesn't mean conventional medicine is wrong. It means the standard of care for this presentation was designed before we knew what we now know, and updating clinical practice takes a decade most patients can't wait.

Get the workup. Name the mechanism. Sequence the recovery.

The label isn't the work.

---

Continue: Klinghardt — Practitioner Who Sees What Conventional Medicine Misses · 5 Levels of Healing · Sarah M. — MTHFR brain-fog case study.